These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 33933376)
1. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Pauwels RWM; van der Woude CJ; Nieboer D; Steyerberg EW; Casanova MJ; Gisbert JP; Kennedy NA; Lees CW; Louis E; Molnár T; Szántó K; Leo E; Bots S; Downey R; Lukas M; Lin WC; Amiot A; Lu C; Roblin X; Farkas K; Seidelin JB; Duijvestein M; D'Haens GR; de Vries AC; Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1671-1686.e16. PubMed ID: 33933376 [TBL] [Abstract][Full Text] [Related]
2. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T; Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404 [TBL] [Abstract][Full Text] [Related]
3. Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies. Ten Bokkel Huinink S; Thomassen D; Steyerberg EW; Pauwels RWM; Casanova MJ; Bouguen G; Mak JWY; Molnár T; Lobo AJ; Seidelin JB; Amiot A; D'Haens G; Rivière P; Guidi L; Bor R; Lin WC; Peyrin-Biroulet L; Gisbert JP; Janneke van der Woude C; de Vries AC J Crohns Colitis; 2024 Jan; 18(1):134-143. PubMed ID: 37437094 [TBL] [Abstract][Full Text] [Related]
4. Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease. Ten Bokkel Huinink S; de Jong DC; Nieboer D; Thomassen D; Steyerberg EW; Dijkgraaf MGW; Bodelier AGL; West RL; Römkens TEH; Hoentjen F; Mallant RC; van Tuyl BAC; Mares WGN; Wolfhagen FHJ; Dijkstra G; Reijnders JGP; de Boer NK; Tan ACITL; van Boeckel PGA; Tack GJ; van Asseldonk DP; D'Haens GRAM; van der Woude CJ; Duijvestein M; de Vries AC Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):983-992. PubMed ID: 36062493 [TBL] [Abstract][Full Text] [Related]
5. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission. Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864 [TBL] [Abstract][Full Text] [Related]
6. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281 [TBL] [Abstract][Full Text] [Related]
7. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. Mak JWY; Tang W; Yip TCF; Ran ZH; Wei SC; Ahuja V; Kumar S; Leung WK; Hilmi I; Limsrivilai J; Aniwan S; Lam BCY; Chan KH; Ng KM; Leung CM; Li MKK; Lo FH; Sze ASF; Tsang SWC; Hui AJ; Hartono JL; Ng SC Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1195-1203. PubMed ID: 31638274 [TBL] [Abstract][Full Text] [Related]
8. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease. Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093 [No Abstract] [Full Text] [Related]
9. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. Song JH; Kang EA; Park SK; Hong SN; Kim YS; Bang KB; Kim KO; Lee HS; Kang SB; Shin SY; Song EM; Im JP; Choi CH; Gut Liver; 2021 Sep; 15(5):752-762. PubMed ID: 33767028 [TBL] [Abstract][Full Text] [Related]
11. Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. Beelen EMJ; Nieboer D; Arkenbosch JHC; Regueiro MD; Satsangi J; Ardizzone S; López-Sanromán A; Savarino E; Armuzzi A; Janneke van der Woude C; de Vries AC Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2741-2752.e6. PubMed ID: 34687970 [TBL] [Abstract][Full Text] [Related]
12. Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients. Kim ES; Kwon Y; Choe YH; Kim MJ Gut Liver; 2022 Jan; 16(1):71-80. PubMed ID: 34092576 [TBL] [Abstract][Full Text] [Related]
13. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E; Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794 [TBL] [Abstract][Full Text] [Related]
14. Development of an MRI-Based Prediction Model for Anti-TNF Treatment Failure in Perianal Crohn's Disease: A Multicenter Study. McCurdy JD; Munir J; Parlow S; Reid J; Yanofsky R; Alenezi T; Meserve J; Becker B; Lahijanian Z; Eddin AH; Mallick R; Ramsay T; Rosenfeld G; Bessissow A; Bessissow T; Jairath V; Singh S; Bruining DH; Macdonald B; Clin Gastroenterol Hepatol; 2024 May; 22(5):1058-1066.e2. PubMed ID: 38122958 [TBL] [Abstract][Full Text] [Related]
15. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773 [TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers. Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111 [TBL] [Abstract][Full Text] [Related]
17. Examination Under Anesthesia May Not Be Universally Required Prior to Anti-TNF Therapy in Perianal Crohn's Disease: A Comparative Cohort Study. Chan M; Fung M; Chin Koon Siw K; Khanna R; de Buck van Overstraeten A; Sabri E; McCurdy JD Inflamm Bowel Dis; 2023 May; 29(5):763-770. PubMed ID: 35815783 [TBL] [Abstract][Full Text] [Related]
18. External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab. Pierre N; Huynh-Thu VA; Baiwir D; Mazzucchelli G; Fléron M; Trzpiot L; Eppe G; De Pauw E; Laharie D; Satsangi J; Bossuyt P; Vuitton L; Vieujean S; Colombel JF; Meuwis MA; Louis E; Gut; 2024 Nov; 73(12):1965-1973. PubMed ID: 39134391 [TBL] [Abstract][Full Text] [Related]
19. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study. Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356 [TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]